Zimmer Biomet Holdings's EBIT per Share for the
three
months ended in Mar. 2026 was CHF1.49.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF4.84.
During the past 12 months, the average EBIT per Share Growth Rate of Zimmer Biomet Holdings was -2.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 6.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 15.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 1.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Zimmer Biomet Holdings's EBIT per Share or its related term are showing as below:
XSWX:ZBH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -21.1 Med: 4.8 Max: 38.7
Current: 6.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Zimmer Biomet Holdings was 38.70% per year. The lowest was -21.10% per year. And the median was 4.80% per year.
XSWX:ZBH's 3-Year EBIT Growth Rate is ranked worse than 53.77% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs XSWX:ZBH: 6.40
Zimmer Biomet Holdings (XSWX:ZBH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Zimmer Biomet Holdings EBIT per Share Related Terms
Zimmer Biomet Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF4.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (XSWX:ZBH) has a EBIT per Share of CHF4.84 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Zimmer Biomet Holdings and its competitors. According to the industry distribution chart, Zimmer Biomet Holdings ranks #371 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 53.8%.
Is Zimmer Biomet Holdings' EBIT per Share too high?
Zimmer Biomet Holdings' current EBIT per Share is CHF4.84. Based on the distribution chart, Zimmer Biomet Holdings ranks #371 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' EBIT per Share compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #371 out of 690 companies for EBIT per Share. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current EBIT per Share is CHF4.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF100.27, compared to a current price of CHF69.50 — trading 30.7% below its estimated fair value. The current EBIT per Share is CHF4.84. Zimmer Biomet Holdings' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current EBIT per Share is CHF4.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF69.50 is trading 30.7% below its estimated GF Value™ of CHF100.27.
GuruFocus considers Zimmer Biomet Holdings to be Significantly Undervalued.
Key valuation signals for XSWX:ZBH:
EBIT per Share: CHF4.84
GF Value™: CHF100.27 vs. price of CHF69.50 (30.7% below fair value)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
69GF Score
Get the complete analysis for XSWX:ZBH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
